Ibraheim E H, El Kappany H, Nigam V N, Brailovsky C A, Madarnas P, Elhilali M M
Anticancer Res. 1984 May-Jun;4(3):209-13.
The prophylactic effect of maltose tetrapalmitate (MTP), a newly developed non specific immunoadjuvant in preventing or delaying bladder cancer induction by N-[4(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) or in reducing the growth rate of the induced tumor was compared to other well-known immunoadjuvants (BCG, C. parvum, levamisole and pyran copolymer). The evaluation of the prophylactic role of immunoadjuvants demonstrated that MTP, levamisole and C. parvum were the most effective in prolonging animal survival. MTP was found superior to either of them in reducing the tumor size. The development of lung metastasis was lower in the group receiving MTP or C. parvum. Next, MTP was studied for its therapeutic effect against primary FANFT induced tumor. The subcutaneous (s.c.) and oral routes of MTP administration and their combination with intravesical route were tried. Combinations of intravesical with s.c. or oral MTP were most effective in reducing tumor size, obtaining lower metastases along with greater mononuclear lymphocyte infiltration in the primary tumor.
将新开发的非特异性免疫佐剂麦芽四棕榈酸酯（MTP）在预防或延缓N-[4（5-硝基-2-呋喃基）-2-噻唑基]甲酰胺（FANFT）诱导膀胱癌或降低诱导肿瘤生长速率方面的预防效果，与其他知名免疫佐剂（卡介苗、短小棒状杆菌、左旋咪唑和聚吡喃共聚物）进行了比较。对免疫佐剂预防作用的评估表明，MTP、左旋咪唑和短小棒状杆菌在延长动物存活时间方面最为有效。在减小肿瘤大小方面，发现MTP优于它们中的任何一种。接受MTP或短小棒状杆菌的组中肺转移的发生率较低。接下来，研究了MTP对原发性FANFT诱导肿瘤的治疗效果。尝试了MTP的皮下（s.c.）和口服给药途径以及它们与膀胱内途径的联合使用。膀胱内与皮下或口服MTP联合使用在减小肿瘤大小、降低转移发生率以及使原发性肿瘤中单核淋巴细胞浸润增加方面最为有效。
